Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS)

BACKGROUND: Subcutaneous administration of Eprex(®) (epoetin alfa) in patients with chronic kidney disease (CKD) was contraindicated in the European Union between 2002 and 2006 after increased reports of anti-erythropoietin antibody-mediated pure red cell aplasia (PRCA). The Prospective Immunogenici...

Descripción completa

Detalles Bibliográficos
Autores principales: Macdougall, Iain C., Casadevall, Nicole, Locatelli, Francesco, Combe, Christian, London, Gerard M., Di Paolo, Salvatore, Kribben, Andreas, Fliser, Danilo, Messner, Hans, McNeil, John, Stevens, Paul, Santoro, Antonio, De Francisco, Angel L.M., Percheson, Paul, Potamianou, Anna, Foucher, Arnaud, Fife, Daniel, Mérit, Véronique, Vercammen, Els
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
CLINICAL SCIENCE
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339685/
https://www.ncbi.nlm.nih.gov/pubmed/25239637
http://dx.doi.org/10.1093/ndt/gfu297

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339685/
https://www.ncbi.nlm.nih.gov/pubmed/25239637
http://dx.doi.org/10.1093/ndt/gfu297

Ejemplares similares